ImmunOS
ImmunOS Pillar VC Powered by ARIA

present London’s first Assay-A-Thon:

Building an Experimental Validation Toolkit for AI-Enabled Discovery

Friday 6 – Sunday 8 November 2026

A weekend for experimental life scientists, engineers and computational experts tackling the validation bottleneck in AI-enabled discovery.

Hosted by ImmunOS and Pillar VC. Powered by ARIA. Partner with us →

Discovery has outpaced validation

The bottleneck in Life Sciences R&D has shifted. AI enabled models propose hypotheses, targets and structures in hours to days. Validation uses experimental infrastructure that requires weeks to months of time and has limited capacity to scale.

The Assay-A-Thon brings experimental, engineering and computational scientists together to ask: what validation toolkit does the new age of AI-enabled discovery need?

ImmunOS is an ARIA Innovation Circle dedicated to understanding immune intelligence: how it senses, computes, controls, and ultimately, how to catalyse translational work in the UK.

  1. 01 AI hypotheses — hours to days Discovery has outpaced validation.
  2. 02 The bench validates — weeks to months Existing validation experiments were not designed for the AI-enabled era.
  3. 03 Assay-A-Thon — validation at AI scale It’s time to build the validation toolkit using the combined insights of AI and experimental scientists.

The challenges

Three gaps in the validation toolkit

ImmunOS has identified three challenges that belong in the validation toolkit: testing designed molecules, building new assay systems, and linking biological state to function — all purpose-built for AI-enabled discovery.

Challenge 1

Protein Design

This challenge focuses on closing the loop between design models and experimental evidence, for target discovery, immune modulation and synthetic circuits.

Read the brief

Structural prediction and generative design tools now produce more candidate binders, enzymes and immune modulators than any lab can test. Most never get past an in-silico confidence score, and the few that do are tested one at a time with assays built for a slower era. This challenge asks teams to build the validation layer: the assays, workflows and decision rules that tell us quickly and cheaply which predictions are real.

Triage at scale

Rank hundreds of designed binders with the cheapest readout that still separates true hits from confident false positives.

From binding to function

Find the early assays that best predict whether a designed immune modulator will work in a cell-based immune assay.

Confidence you can trust

Benchmark model confidence scores against experimental data. When should we believe the model?

Learning from failure

Capture negative results in a standard form so they can feed back into the next round of design.

Designing for the assay

Build validation in from the start. Which design choices make a protein easier to test?

Challenge 2

Prototyping Assays

This challenge focuses on prototyping hardware for next-generation assays for complex models and automated workflows.

Read the brief

Automated labs can run experiments around the clock, but they are limited by the hardware they are given. Many of the measurements that would best test an AI prediction need physical control a standard plate cannot provide: precise fluid handling, defined cell environments, or cells placed exactly where a model says they should interact. Teams in this challenge design and prototype that hardware, either built on site with 3D printers and laser cutters or as a fully specified design.

Microfluidics

Modules for droplet generation, gradient formation or sorting that can be printed, cut and assembled cheaply.

Environmental control

Devices that set oxygen, shear, temperature or confinement so assay conditions are reproducible across labs.

Spatial patterning

Tools that position cells or reagents to test predicted cell–cell interactions.

Automation-ready

Open, low-cost hardware that docks into liquid handlers and cloud labs rather than living on one bench.

Readouts

Simple sensors or imaging set-ups that turn a manual bench assay into a continuous data stream.

Challenge 3

Functional Omics Assays

This challenge focuses on high-throughput functional assays spanning sample and library prep, omics and NGS workflows, and functional readouts.

Read the brief

Omics technologies enable high-dimensional measurement of biological responses at scale, while AI models increasingly aim to predict those responses. Yet functional validation remains harder to scale: many phenotypic assays are lower-throughput, costly, or difficult to manufacture and deploy reproducibly. This challenge asks teams to develop assays that capture functional readouts leveraging omics infrastructure to improve the throughput and standardization of experimental validation, making it possible to test AI-generated hypotheses at scale.

Link state to function

Connect molecular profiles to functional readouts such as secretion, killing and migration in the same cells.

Do more with less

Design assays to find the minimum cells, perturbations and conditions needed to confirm or refute a model prediction.

Ground truth for models

Design assays to generate benchmark datasets designed to reveal where predictions succeed and fail.

Measure function at scale

Make functional phenotyping higher-throughput and more cost-effective, particularly for complex immune-cell behaviors.

Who should apply

You might be…

The Assay-A-Thon is built around the value of intersectional collaboration. We are looking for experimental, engineering, and computational scientists who are interested in bridging the gap between a hypothetical target and a validated result.

Wet-lab scientists

Assay development, protein biochemistry, cell biology, immunology, single-cell and NGS workflows.

Engineers

Materials, 3D printing and modelling, hardware, instrumentation, microfluidics and lab automation.

Computational scientists

Protein design and ML, bioinformatics, statistics, data and pipeline engineering.

Who is eligible
PhD students, postdocs, industry scientists and engineers, and founders — from academia, biotech or industry.
Location
Open to applicants anywhere who can attend in person in London.
Apply as
Individuals or pre-formed teams of 4–5. Solo applicants are matched into mixed wet-lab, computational and engineering teams.
Places
9 teams (3 per challenge) of 4–5 people — roughly 36–45 participants.
On site
3D printers and laser cutters for prototyping. Solutions can be hardware or theoretical.
Bring
Laptop, charger and any files or materials you want to prototype with.
Food
All meals provided; dietary requirements collected on the application form.
Accessibility
Need adjustments? Email research@immunos.bio and we will work with you.
IP
Teams own what they build.

How to Apply

Apply to attend by Monday the 2nd of November. Organisers review applications on a rolling basis and send invitations, so apply early.

We select for: Relevant skills, motivation, and the mix each applicant adds to a team across wet-lab, computational and engineering expertise.

Apply now
  1. 21 October 2026 Applications open
  2. Monday 2 November 2026 Application deadline
  3. Rolling Decisions sent
  4. Online, w/c 2 November Pre-event briefing / team matching Challenge briefs and team matching for solo applicants
  5. 6–8 November 2026 Event
  6. Winners on Sun 8 Nov; recap w/c 16 Nov Winners announced / recap published Recap on The ImmunOS Dispatch

The Agenda

Fri 6 Nov

  • 17:00 Registration
  • 17:30 Welcome and challenge briefs
  • 18:30 Networking + team formation

Sat 7 Nov

  • 09:00 Breakfast + orientation
  • 09:30–12:00 Build session
  • 12:00–13:00 Lunch + mentor intros
  • 13:00–19:00 Build session 2 + mentor check-in

Sun 8 Nov

  • 09:00 Breakfast; final build and demo prep
  • 14:30 Demos + pitches and judging
  • 16:30 Awards — Litmus Science Validation Prize and additional prizes
  • 17:15 Closing drinks + networking (doors close 18:00)

Judging & prizes

Provided by Litmus Science

Litmus Science Validation Prize

Whether it's a new binder, a new assay or a new device, the Litmus Science Validation Prize gives the winning team a funded, head-to-head experiment against the existing validation gold standard in a real lab, and the first real evidence of what their idea can do.

Additional prizes, including validation resources and bench access — announcing soon.

What the judges look for

Scientific rigour
Does the validation answer the question the AI output actually poses?
Technical feasibility & build quality
Does the prototype or assay work, and could it be built again?
Scalability
Could it run at AI scale or plug into automated labs?
Translational / commercial potential
Is there a path to real-world use?
Live demo
Clarity of the targeted problem and solution.

Meet Our Partners

Hosted by

Judges

Founders, investors and hardware and AI leaders judging technical feasibility, build quality and translational potential.

Assay-A-Thon Sponsorship opportunities

We are still welcoming partners and mentors. Partners can offer prizes, prototyping credits, CAD and print licences, reagents, bench access, compute or follow-on mentorship, and in return get co-branding across the event and recap, and first look at the tools, teams and methods that emerge.

Get in touch

Powered by ARIA

The Assay-A-Thon is designed by ImmunOS, an ARIA Innovation Circle exploring the immune system through the lens of an operating system. Our focus on immunity closely aligns with ARIA’s Sustained Viral Resilience programme, which is developing new approaches, tools and platforms for engineering innate immunity. The Assay-A-Thon extends this shared ambition by tackling a critical bottleneck: scalable experimental validation for AI-enabled biology. Read more about ARIA’s Sustained Viral Resilience programme.

Read more about ARIA’s Innovator Circles here.

Powered by ARIA

Assay-A-Thon · London · 6–8 November 2026

FAQs · research@immunos.bio · Subscribe to The ImmunOS Dispatch for the event recap

By attending, you agree that you may appear in event photography and video. Tell us on arrival if you would prefer not to.